RenovoRx

Los Altos, United States Founded: 2009 • Age: 17 yrs Listed
Developing endovascular catheters for targeted delivery of IV fluids to peripheral organs

About RenovoRx

RenovoRx is a publicly listed company based in Los Altos (United States) founded in 2009. RenovoRx has raised $10.91 million across 7 funding rounds from investors including Boston Scientific, BtoV and Astia. The company has 10 employees. RenovoRx offers products and services including RenovoCath Device and TAMP Therapy Platform. Its focus areas include Life Sciences, Drug Delivery, Intravenous and Oncology. Its legal entity is RENOVORX, INC. Its competitors include Moderna, BeiGene and Insulet; 3 of its 3 listed competitors have raised funding.

Company details

Developing endovascular catheters for targeted delivery of IV fluids to peripheral organs. It develops endovascular catheters for the visceral and peripheral vascular systems. The RenovoRx device can be used to deliver both therapeutic(such as drugs)and diagnostic fluids(such as contrast agents) to the target organ through veins. The device allows for isolated vessel perfusion i.e. a balloon is inflated within the blood vessels to block blood flow to other organs to maximize the amount of blood flow(and IV fluids reaching the target organ.

Key Metrics
  • Annual Revenue
    $1.12 M (USD)
    2511.63
    as on Dec 31, 2025
  • Net Profit
    -$11.17 M (USD)
    -26.71
    as on Dec 31, 2025
  • EBITDA
    -$12.51 M (USD)
    -14.02
    as on Dec 31, 2025
  • Total Equity Funding
    $10.91M (USD)

    in 7 rounds

  • Latest Funding Round
    $10M (USD), Post-IPO

    Mar 2026

  • Investors
  • Employee Count
    10

Products & Services of RenovoRx

RenovoRx offers a comprehensive portfolio of products and services, including RenovoCath Device and TAMP Therapy Platform.

RenovoCath Device
Medical Device

FDA-cleared device for targeted drug delivery in oncology treatments.

TAMP Therapy Platform
Therapy Platform

Platform for precise intra-arterial drug administration to minimize side effects.

Apps and channels of RenovoRx

its YouTube channel RNXT (RenovoRx) has 31 subscribers and 8 videos.

RNXT (RenovoRx)
YouTube 31 subscribers 8 videos Science & Technology
Open channel

Videos from RenovoRx

The most watched videos on RenovoRx's YouTube channel, RNXT (RenovoRx) (31 subscribers). Click a video to play it here.

The RenovoRx Story with CEO, Shaun Bagai
313 views
The RenovoRx Story: Fighting Difficult-to-Treat Cancers via Localized Treatment
266 views
Delivering Therapy Where It Matters - Webinar of 2/23/22
248 views
Facing Today’s Challenges in Pancreatic Cancer Treatment - Webinar of 6/21/22
242 views

More on RNXT (RenovoRx).

Funding Insights of RenovoRx

RenovoRx has successfully raised a total of $10.91M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $10.91M
  • Total Rounds 7
  • Last Round Post-IPO — $10M
  • First Round $660,000

    (Apr 2013)

  • Investors Count 9

All 7 funding rounds of RenovoRx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2026$10MPost-IPO––
–
Apr 2024$11.14MPost-IPO––
–
Jan 2024Post-IPO––
–
May 2018$7MSeries D–Boston Scientific
Dec 2015$2.1MSeries C––
–
Jan 2014$1.15MSeries B–Golden Seeds
Apr 2013$660,000Series A––
–
Valuation history

9 investors in total: 9 institutional.

Investors in RenovoRx

RenovoRx has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Boston Scientific, BtoV and Astia.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Stage agnostic VC firm funding companies in Europe
btov.vcBerlin, Germany
Women-led startups are funded through stage-agnostic investments and angel networks.
astia.orgSan Francisco, United States
Tech & Life Sciences focused VC firm investing in early stage startups in the US
angelsforum.comMountain View, United States
halofund.com
Tech & Life-Sciences focused VC Firm investing in the US
goldenseeds.comNew York, United States
Early-stage life science and technology startups are supported.
acorntaiwan.comSanta Clara, United States
Angel funding is provided to Silicon Valley-based companies.
sandhillangels.comMountain View, United States
Seed and early-stage investments are focused on US companies.
amidzad.comRedwood City, United States
Wide range of medical devices
1979bostonscientific.comMarlborough, United States
Premium access

Investor details for RenovoRx

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of RenovoRx

18 people are tracked at RenovoRx (9 in leadership, 8 in board & advisors, 1 in team); the tracked headcount is 10.

NameRoleGroup
Robert Strasser
VP Operations And R&dLeadership
James Ahlers
CFOLeadership
Ronald B. Kocak
Vice President & ControllerLeadership
Shaun R. Bagai
CEOLeadership
Ramtin Agah
Chief Medical Officer & FounderLeadership
Philip Stocton
Sr. Global Director Sales And Market DevelopemntLeadership
Imtiaz Qureshi
Director, ImagingLeadership
Neil Sankar M.D.,MPH
Sr Medical Director and Medical Monitor Consultant Medical Oncology ProgramsLeadership
Ryan Witt
Svp, Head Of Corporate Strategy & PartnershipsLeadership
Una S. Ryan
DirectorBoard & advisors
Laurence J. Marton
DirectorBoard & advisors
Mike Pishvaian
AdvisorBoard & advisors
Margaret A. Tempero
Scientific Advisory Board MemberBoard & advisors
Angela MacFarlane
DirectorBoard & advisors
David Diamond
DirectorBoard & advisors
Karyn A. Goodman
AdvisorBoard & advisors
Robert J. Spiegel
DirectorBoard & advisors
Leesa Gentry
SVP, Clinical OperationsTeam
Premium access

Complete people profiles for RenovoRx

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of RenovoRx

RenovoRx is a publicly listed company on the NASDAQ with ticker symbol RNXT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date26 Aug 2021
  • Listed onNASDAQ: RNXT
  • Listed entityRenovoRx, Inc.
  • Exchange sectorHealth technology
  • ISINUS75989R1077
  • Share price$1.15 (-8% on the day) · 2026-10-13
  • Market capitalisation$51.9M
  • EPS (diluted, trailing year)$-0.31
  • Volume (last session)942,432

Financials of RenovoRx

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$1.1M-$11.2M-$12.5M
2024$43,000-$8.8M-$11.0M
2023-$10.2M-$11.4M
2022-$9.9M-$9.9M
2021-$6.3M-$5.7M
Premium access

Detailed financial statements for RenovoRx

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of RenovoRx

4 dated milestones of RenovoRx across 17 years, from founding to its latest funding, stage changes and deals.

  1. Founded RenovoRx is founded.
  2. Funding First funding round of $660K.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $10.0M.

Competitors of RenovoRx

RenovoRx has 3 listed competitors in our database, 3 of them funded. They include Moderna, BeiGene and Insulet.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
modernatx.com2010Cambridge, United States$2.78B1,312
mRNA-based therapeutics for diseases including cancer and infections are developed.
beigene.com2010Cambridge, United States$172M1,090
Targeted and immune-oncology drugs for cancer treatment are developed.
insulet.com2000Boston, United States$120.4M2,600
Wearable insulin infusion systems are developed for diabetes patients.
Premium access

Detailed competitors of RenovoRx

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of RenovoRx

The website of RenovoRx (renovorx.com) receives about 6K visits a month.

  • Monthly visits
    6K

    ▲ 70.7% vs previous month

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as RenovoRx (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Suite solutions are provided for payers and healthcare providers.
1998Princeton, New Jersey, United StatesUSD 220 MUSD 374.1 M5,666
Wearable insulin infusion systems are developed for diabetes patients.
2000Boston, Massachusetts, United StatesUSD 120.4 MUSD 2.71 B3,900
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Renovorx

Premium access

Complete news archive for RenovoRx

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about RenovoRx

RenovoRx was founded in 2009 and raised its 1st funding round 4 years after it was founded.

RenovoRx is headquartered in Los Altos, United States. It is registered at Los Altos, California, United States.

RenovoRx is a funded company, having raised a total of $10.91M across 7 funding rounds to date. The company's 1st funding round was a Series A of $660K, raised on Apr 2013.

RenovoRx has 10 employees.

Annual revenue of RenovoRx is $1.12M as on Dec 31, 2025.

Developing endovascular catheters for targeted delivery of IV fluids to peripheral organs. It develops endovascular catheters for the visceral and peripheral vascular systems. The RenovoRx device can be used to deliver both therapeutic(such as drugs)and diagnostic fluids(such as contrast agents) to the target organ through veins. The device allows for isolated vessel perfusion i.e. a balloon is inflated within the blood vessels to block blood flow to other organs to maximize the amount of blood flow(and IV fluids reaching the target organ.

RenovoRx's top competitors include Moderna, Insulet and BeiGene.

RenovoRx offers RenovoCath Device and TAMP Therapy Platform.

Yes, RenovoRx is publicly traded on NASDAQ under the ticker symbol RNXT.

RenovoRx has 9 investors. Key investors include Boston Scientific, BtoV, Astia, The Angels’ Forum, and The Halo Fund.

RenovoRx operates through Renovorx, Inc..

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available